REFERENCES
1. DeFronzo R., Mehta R., Schnure J. Pleiotropic effects of thiazoli-dinediones: implications for the treatment of patients with type 2 diabetes mellitus. Hosp Pract. 2013; 41 (2): 132-47. DOI: https://doi.org/10.3810/hp.2013.04.1062
2. Bogacka I., Xie H., Bray G.A., et al. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 2004; 27 (7): 1660-7. DOI: https://doi.org/10.2337/diacare.27.7.1660
3. Smith S., De Jonge L., Volaufova J., et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism. 2005; 54 (1): 24-32. DOI: https://doi.org/10.1016/j.me-tabol.2004.07.008
4. Mudaliar S., Chang A., Henry R. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract. 2003; 9 (5): 406-16. DOI: https://doi.org/10.4158/EP.9.5.406
5. Nakano K., Hasegawa G., Fukui M., et al. Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes. Endocr J. 2010; 57 (5): 423-30. DOI: https://doi.org/10.1507/endocrj.K10E-006
6. Goldberg R., Kendall D., Deeg M., et al. A Comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005; 28 (7): 1547-54. DOI: https://doi.org/10.2337/diacare.28.7.1547
7. Kernan W., Viscoli C., Furie K., et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016; 374: 1321-31. DOI: https://doi.org/10.1056/NEJMoa1506930
8. Defronzo R., Tripathy D., Schwenke D., et al. ACT NOW Study. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes. 2013; 62 (11): 3920-6. DOI: https://doi.org/10.2337/db13-0265
9. Schernthaner G., Matthews D., Charbonnel B., et al.; Quartet Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a doubleblind, randomized trial. J Clin Endocrinol Metab. 2004; 89: 6068-76. DOI: https://doi.org/10.1210/jc.2003-030861
10. Gastaldelli A., Harrison S., Belfort-Aguiar R., et al. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther. 2010; 32 (6): 769-75. DOI: https://doi.org/10.1111/j.1365-2036.2010.04405.x
11. Nyland J., Raja-Khan N., Bettermann K., et al. Drug treatment and mortality in COVID-19: a multinational retrospective cohort study. Diabetes 2021; 70 (10): db210385. DOI: https://doi.org/10.2337/db21-0385
12. Kaku K., Kisanuki K., Shibata M., et al. Benefit-risk assessment of alogliptin for the treatment of type 2 diabetes mellitus. Drug Saf. 2019; 42: 1311-27. DOI: https://doi.org/10.1007/s40264-019-00857-8
13. White W., Heller S., Cannon C., et al. Alogliptin in patients with type 2 diabetes on metformin and sulfonylurea therapies in the EXAMINE trial. Am J Med. 2018; 131 (7): 813-9. DOI: https://doi.org/10.1016Aam-jmed.2018.02.023
14. Ferreira J., Mehta C., Sharma A., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial. BMC Med. 2020; 18 (1): S 165. DOI: htpps://doi.org/10.1186/s12916-020-01616-8
15. Yoshida M., Mita T., Yamamoto R., et al. Combination of the Framingham risk score and carotid intima-media thickness improves the prediction of cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2012; 35: 178-80. DOI: https://doi.org/10.2337/dc11-1333
16. Mita T., Katakami N., Yoshii H., et al. Alogliptin, a dipeptidyl peptidase-4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care. 2015; 39 (1): 139-48. DOI: https://doi.org/10.2337/dc15-0781
17. Kikuchi S., Okada K., Hibi K. TCT-835 impact of early intervention with alogliptin on coronary plaque regression in patients with acute coronary syndromes: a prospective, single-center, randomized trial. J Am Coll Cardiol. 2019; 74 (13): B 818. DOI: htpps://doi.org/10.1016/j.jacc.2019.08.984
18. Tanaka R., Yamashiro K., Nobukazu M. Efficacy of alogliptin (DPP-4 inhibitor) for the secondary prevention after ischemic stroke or TIA with type 2 diabetes mellitus. Poster Abstracts. Eur Stroke J. 2017; 2: 98-476. DOI: https://doi.org/10.1177/2396987317705242
19. Ofulue F., Thurlbeck W. Experimental diabetes and the lung. II. In vivo connective tissue metabolism. Am Rev Respir Dis. 1988; 138 (2): 284-9. DOI: https://doi.org/10.1164/ajrccm/138.2.284
20. Hsia C., Raskin P. Lung function changes related to diabetes mellitus. Diabetes Technol Ther. 2007; 9 (1): 73-82. DOI: https://doi.org/10.1089/dia.2007.0227
21. Lazarus R., Sparrow D., Weiss S.T. Handgrip strength and insulin levels: cross-sectional and prospective associations in the Normative Aging study. Metabolism. 1997; 46 (11): 1266-9. DOI: https://doi.org/10.1016/S0026-0495(97)90228-6
22. Tai H., Wang M., Zhao Y., et al. The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy. Medicine (Baltimore). 2016; 95 (33): e4541. DOI: htpps://doi.org/10.1097/MD.0000000000004541
23. Van Raalte D., van Genugten R., Eliasson B., et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of p-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014; 170 (4): 565-74. DOI: https://doi.org/10.1530/EJE-13-0639
24. Aoki C., Suzuki K., Kuroda H., et al. Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index. Nagoya J Med Sci. 2017; 79 (1): 9-16. DOI: htpps://doi.org/10.18999/nagjms.79.1.9
25. Amano Y., Tsuchiya S., Imai M., et al. Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. Biochem Biophys Res Commun. 2018; 497 (1): 207-13. DOI: https://doi.org/10.1016Abbrc.2018.02.055
26. Bosi E., Ellis G., Wilson C., et al. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011; 13 (12): 1088-96. DOI: https://doi.org/10.1111/j.1463-1326.2011.01463.x
27. Rosenstock J., Inzucchi S.E., Seufert J., Fleck P.R., Wilson C.A., Mekki Q. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010; 33 (11): 2406-8. DOI: https://doi.org/10.2337/dc10-0159
28. Marino A.B., Cole S.W. Alogliptin: safety, efficacy, and clinical implications. J Pharm Pract. 2015; 28 (1): 99-106. DOI: https://doi.org/10.1177/0897190014522063
29. DeFronzo R.A., Burant C.F., Fleck P., Wilson C., Mekki Q., Pratley R.E. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97 (5): 1615-22. DOI: https://doi.org/10.1210/jc.2011-2243